In patients with high MALAT1 expression, it was found that MALAT1 binds EZH2 to the CDH1 promoter and inhibits miR-218 during oxaliplatin treatment, indirectly promoting EMT, metastasis, and chemoresistance of colorectal cancer cells. This evidence concerns the gene MALAT1 and colorectal cancer.